Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Rethinking new therapies for Crohn’s disease at U.Va.

12.11.2004


In a Perspective article in the Nov. 11 issue of the New England Journal of Medicine, Dr. Fabio Cominelli, chief of the division of gastroenterology and hepatology at the University of Virginia Health System reports that a dysregulated response by the innate immune system- the body’s initial, non-specific response to infection- may have more to do with the development of Crohn’s than acquired immunity, currently thought by many to be the most likely suspect.



Patients, physicians and medical researchers need to reconsider traditional hypotheses about the biological processes that underlie Crohn’s disease, according to Cominelli, a leading Crohn’s expert. More than half a million people in the U.S. suffer from Crohn’s,a chronic disease involving inflammation of the intestines.

Cominelli indicates that more cytokines- proteins that coordinate the immune response in inflammation- may be involved in Crohn’s than scientists had previously thought. He believes that a growing body of evidence shows that both type 1 and type 2 helper T-cells are likely involved in the early stages of Crohn’s disease. The classic paradigm held that cytokines secreted by type 1 T-cells, such as TNF (tumor necrosis factor), interleukin-12 and interferon-g were primarily responsible for Crohn’s, while type 2 cytokines were linked to ulcerative colitis, another type of inflammatory bowel disease.


Although the underlying cause of Crohn’s remains unclear, Cominelli describes an intriguing hypothesis in which a defective innate immune system may be an important player. This could mean that blocking specific type 1 cytokines in the initial phases of Crohn’s “may not be beneficial and could actually aggravate the existing disease process,” he writes.

Cominelli emphasizes that there are questions about infliximab, the first biological therapeutic approved to treat Crohn’s, which blocks the production of the type 1 cytokine TNF. He points out that infliximab therapy does not relieve Crohn’s symptoms or induce remission in some patients. Plus, type 1 cytokines are important in combating infections, and blocking them can reactivate latent tuberculosis in some patients.

Cominelli also warns that anti-cytokine therapy in general may increase the long-term risk of cancer, and blocking some cytokines may reactivate asthma. “An effective treatment strategy for such patients might involve the blockade of multiple cytokines in order to intervene in several pathways,” he concludes.

Bob Beard | EurekAlert!
Further information:
http://www.virginia.edu

More articles from Health and Medicine:

nachricht Indications of Psychosis Appear in Cortical Folding
26.04.2018 | Universität Basel

nachricht GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Why we need erasable MRI scans

New technology could allow an MRI contrast agent to 'blink off,' helping doctors diagnose disease

Magnetic resonance imaging, or MRI, is a widely used medical tool for taking pictures of the insides of our body. One way to make MRI scans easier to read is...

Im Focus: BAM@Hannover Messe: innovative 3D printing method for space flight

At the Hannover Messe 2018, the Bundesanstalt für Materialforschung und-prüfung (BAM) will show how, in the future, astronauts could produce their own tools or spare parts in zero gravity using 3D printing. This will reduce, weight and transport costs for space missions. Visitors can experience the innovative additive manufacturing process live at the fair.

Powder-based additive manufacturing in zero gravity is the name of the project in which a component is produced by applying metallic powder layers and then...

Im Focus: Molecules Brilliantly Illuminated

Physicists at the Laboratory for Attosecond Physics, which is jointly run by Ludwig-Maximilians-Universität and the Max Planck Institute of Quantum Optics, have developed a high-power laser system that generates ultrashort pulses of light covering a large share of the mid-infrared spectrum. The researchers envisage a wide range of applications for the technology – in the early diagnosis of cancer, for instance.

Molecules are the building blocks of life. Like all other organisms, we are made of them. They control our biorhythm, and they can also reflect our state of...

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

World's smallest optical implantable biodevice

26.04.2018 | Power and Electrical Engineering

Molecular evolution: How the building blocks of life may form in space

26.04.2018 | Life Sciences

First Li-Fi-product with technology from Fraunhofer HHI launched in Japan

26.04.2018 | Power and Electrical Engineering

VideoLinks
Science & Research
Overview of more VideoLinks >>>